



Published in final edited form as:

J Bone Miner Res. 2019 July ; 34(7): 1284–1296. doi:10.1002/jbmr.3698.

Meta-Analysis of Genomewide Association Studies Reveals Genetic Variants for Hip Bone Geometry

A full list of authors and affiliations appears at the end of the article.

Abstract

Hip geometry is an important predictor of fracture. We performed a meta-analysis of GWAS studies in adults to identify genetic variants that are associated with proximal femur geometry phenotypes. We analyzed four phenotypes: (i) femoral neck length; (ii) neck-shaft angle; (iii) femoral neck width, and (iv) femoral neck section modulus, estimated from DXA scans using algorithms of hip structure analysis. In the Discovery stage, 10 cohort studies were included in the fixed-effect meta-analysis, with up to 18,719 men and women ages 16 to 93 years. Association analyses were performed with ~2.5 million polymorphisms under an additive model adjusted for age, body mass index, and height. Replication analyses of meta-GWAS significant loci (at adjusted genomewide significance [GWS], threshold $p = 2.6 \times 10^{-8}$) were performed in seven additional cohorts in silico. We looked up SNPs associated in our analysis, for association with height, bone mineral density (BMD), and fracture. In meta-analysis (combined Discovery and Replication stages), GWS associations were found at 5p15 (*IRX1* and *ADAMTS16*); 5q35 near *FGFR4*; at 12p11 (in *CCDC91*); 11q13 (near *LRP5* and *PPP6R3* (rs7102273)). Several hip geometry signals overlapped with BMD, including *LRP5* (chr. 11). Chr. 11 SNP rs7102273 was associated with any-type fracture ($p = 7.5 \times 10^{-5}$). We used bone transcriptome data and discovered several significant eQTLs, including rs7102273 and *PPP6R3* expression ($p = 0.0007$), and rs6556301 (intergenic, chr.5 near *FGFR4*) and *PDLIM7* expression ($p = 0.005$). In conclusion, we found associations between several genes and hip geometry measures that explained 12% to 22% of heritability at different sites. The results provide a defined set of genes related to biological pathways relevant to BMD and etiology of bone fragility.

Keywords

HIP BONE GEOMETRY; FRACTURE; GENOMEWIDE ASSOCIATION STUDY; META-ANALYSIS; CANDIDATE GENES; POLYMORPHISMS

Address correspondence to: David Karasik, PhD, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed 1311502, Israel. karasik@hsl.harvard.edu.

*KE and EE contributed equally to this work.

Authors' roles: Study design: YHH, TB, AU, FR, DPK, DK. Study conduct: TB, TC, JC, CLC, SRC, KG, AK, DAL, MLo, BM, AN, CN, MP, JBR, JR, GS, KS, ES, US, JT, SW, CZ. Data collection: KA, TB, SB, LC, JC, CLC, SRC, SC, ME, KG, TH, CK, JK, ML, MLo, FMG, CMG, BM, AN, CN, CO, MP, SR, JBR, JR, GS, TS, ES, US, JT, LV, SW, MY, FR, DPK, DK. Data analysis: YHH, KE, EE, SB, SD, DE, JK, DLK, ML, FMG, CMG, CN, KT, LV, LYA. Data interpretation: CAB, KA, TB, TC, CLC, ME, CF, KG, DAL, CMG, CO, SR, KT, SW, CZ. Drafting manuscript: YHH, KE, EE, CLC, FMG, SR, DK. Revising manuscript content: CAB, TB, TC, CF, ML, JT, FR, SW, DPK. Approving final version of manuscript: YHH, KE, EE, SC, ME, TH, AK, BM, AN, CO, TS, AU, DPK. DK takes responsibility for the integrity of the data analysis.

Disclosures

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Introduction

Osteoporosis and associated fractures are common world-wide. In the United States alone, a total of 340,000 hip fractures occur each year, and the number of hip fractures is predicted to more than triple worldwide from 1.66 million in 1990 to 6.26 million in 2050.⁽¹⁾ In older individuals, hip fractures are a source of increased mortality, morbidity, and healthcare expenses. They are associated with a more than twofold increase in the likelihood of mortality, a fourfold increase in the probability of requiring institutional care, and a twofold increase in entering low-income status 1 year postfracture as compared to patients who do not sustain hip fractures.⁽²⁾ Hip fractures may be preventable in as many as 50% of cases through the use of the available pharmacotherapies,⁽³⁾ but improvements in the identification of high-risk patients are necessary.^(4,5)

The most often studied phenotype for genetic studies of osteoporosis is bone mineral density (BMD) as assessed by dual-energy X-ray absorptiometry (DXA) of the hip. BMD is a two-dimensional measure and does not account for the cross-sectional distribution of bone mass in the femur. BMD is an imperfect predictor of hip fracture and increasing attention has focused on contribution of other factors to bone strength, such as hip geometry.^(6,7) Indeed, hip geometry traits have been associated with fracture risk, independent of BMD in most,^(8–11) but not all, studies.⁽¹¹⁾ Like BMD, hip geometry traits have a strong genetic component with a heritability of 28% to 70%.⁽¹²⁾ Although some candidate-gene association studies^(13–15) and modest-size genomewide association studies (GWASs) have been performed,^(16–18) a powerful large-scale GWAS meta-analysis is essential in order to provide a comprehensive picture of the genetic architecture of hip geometry and to determine if novel genetic pathways independent of (BMD) BMD influence hip geometry. Understanding the genetics of hip geometry provides the potential to identify additional genetic architecture of fracture risk above and beyond BMD. There is also a complex relationship between adult height, bone geometry, and fracture risk. The premise of this study is that geometry of the proximal femur influences its predilection to fracture and that genetic factors responsible for determining the geometric features of the proximal femur could be involved in hip fracture risk.

In this study we performed a GWAS discovery analysis of hip geometry indices measured by DXA-derived hip structural analysis conducted on a large sample of women and men of predominantly European ancestry from the cohorts of the Genetic Factors for Osteoporosis (GEFOS) consortium.⁽¹⁹⁾ The model adjusted for covariates, including body mass index (BMI) and height, was tested. This was followed by replication of the top findings in seven additional independent human cohorts. In order to prioritize variants that were novel for hip geometry, we then determined whether the genomewide association findings had also been found in previous GWASs of BMD phenotypes, height, or fracture. Finally, we assessed the functional relevance of the identified loci for bone biology using information from relevant sources, including gene expression data on cellular or whole animal models, as well as transcriptome and experimental studies in skeletal biopsies from human donors.

Methods

Study subjects and hip geometry phenotypes

The Discovery stage of this study utilized data from 10 cohort studies and totaled data from 18,719 adult men and women for whom genomewide SNP data and relevant hip geometry phenotypes were available. These individuals were from populations across North America, Europe, and East Asia, members of the Genetic Factors for Osteoporosis (GEFOS) consortium (Supporting Table 1a). The GEFOS consortium is an international collaboration of investigators dedicated to the identification of genetic determinants of osteoporosis and fragility fracture.^(20–22) Additional descriptive information about the participating cohorts is available in Supporting Table 1a. Supporting Figure 1 illustrates the general schematic representation of the present study design.

We sought *in silico* independent replication, using summary results from seven cohorts ($n = 8334$ men and women) with genomewide SNP data that became available after the initial discovery meta-analysis was completed. Characteristics of the replication cohorts are summarized in Supporting Table 1b. All studies were approved by institutional ethics review committees at the relevant organizations and all participants provided written informed consent.

Hip geometry measures were derived from DXA scans using the Hip Structural Analysis (HSA)⁽²³⁾ algorithm or a software supplied by a DXA machine manufacturer (see Supporting Table 1a,b). In each cohort study the following hip geometry indices were measured: femoral neck length (FNL), neck-shaft angle (NSA), the narrowest width of the femoral neck (NNW), and its section modulus (NNZ).⁽¹²⁾ Coefficients of variation for hip geometry traits were reported to range from 3.3% (NN outer diameter) to 9.1% (FNL).⁽²⁴⁾

In each cohort, at the time of the DXA exam or on a visit preceding it, standing height was measured and BMI calculated (Supporting Table 1a,b).⁽²⁵⁾

GWAS of bone phenotypes

Genotyping and imputation methods—All the cohorts were genotyped using commercially available Affymetrix (Affymetrix Inc., Santa Clara, CA, USA) or Illumina (Illumina Inc., San Diego, CA, USA) genotyping arrays (Supporting Table 2). Quality control was performed independently in each study according to standard manufacturer-provided protocols and within study procedures. To facilitate meta-analysis, each group performed genotype imputation with IMPUTE⁽²⁶⁾ or MACH⁽²⁷⁾ software (see Supporting Table 2 for details) using genotypes from the HapMap Phase II release 22, NCBI build 36 (CEU or CHB/JPT as appropriate [for Hong-Kong cohort]) as reference panels. More recent reference panels such as HRC42 were not available at the time of the analyses. Each imputation software provides an overall imputation quality score for each single-nucleotide polymorphism (SNP). Analysis of imputed genotypes used either the dosage information from MACH or the genotype probabilities from IMPUTE (Supporting Table 2). Before performing an analysis, poorly imputed and low-frequency or rare polymorphisms were excluded. Specifically the quality control filters applied for exclusions of SNPs were: imputation quality score <0.3 for MACH and <0.4 for IMPUTE, average minor allele

frequency (MAF) of <1% across studies, and SNPs missing from ~50% of the cohorts contributing to each outcome (at the meta-analysis stage). After quality control, up to ~2.5 million SNPs were available from each cohort for the Discovery meta-analysis.

Association analyses—In the Discovery phase, each cohort conducted analyses according to a standard prespecified analysis plan under an additive (ie, per allele count) genetic model. Phenotypes were defined as the sex-specific standardized residuals derived from linear regression of each outcome variable on age, age², BMI, and height. The assumption of normality of residuals in the linear regression model was checked within each cohort for each phenotype and no deviations were reported. The SNP–phenotype associations in each study were adjusted for potential confounding by population substructure using principal components as appropriate; pedigree and twin-based studies additionally corrected for family structure (using the R Kinship2 package: https://cran.r-project.org/web/packages/available_packages_by_name.html). Sex-specific analyses were performed, except for the family-based cohorts, where combined-sex models were generated with additional adjustment for sex. Cohort-specific summary statistics (beta-coefficients, standard errors, and *p* values) were used for the meta-analysis of each outcome variable (standardized residuals of FNL, NSA, NNW, and NNZ) with the genomewide SNPs. The replication analyses used the same analytical procedures as the Discovery analyses (eg, using study-specific standardized residuals from the covariate-adjusted model, as outcomes).

Meta-analysis—Meta-analysis of the GWAS discovery results was conducted and tested independently in two collaborating centers (Broad Institute and Hebrew SeniorLife, both in Boston, MA, USA). Because of potential power limitations to detect sex-specific associations (*n* males = 5510, *n* females = 11,701, see Supporting Table 1), we performed sex-combined meta-analysis. A fixed effects, sample size–weighted meta-analysis (using METAL software) was conducted in the Discovery set. Double genomic correction to control for potential inflation of the test statistics was performed, in individual studies and in the meta-analysis. The genomewide level of statistical significance (GWS) after adjustment for multiple correlated traits (effective *n* = 1.92), was set at $p = 2.6 \times 10^{-8}$ and the suggestive level of significance at $p < 5 \times 10^{-6}$. The quantile-quantile (QQ) plots were generated for each phenotype, by pruning association results at a linkage disequilibrium (LD) threshold of 0.50 (calculated with SNAP⁽²⁸⁾ using 1000 Genomes⁽²⁹⁾ data). Regional plots were generated with LocusZoom with modifications,⁽³⁰⁾ using chromosome position coordinates as provided in GrCh37/hg19.

In silico Replication and Combined meta-analysis—Because the in silico replication was performed in cohorts with existing genomewide data (and not by de novo genotyping), all the region-wide SNPs in the LD (r^2 threshold of 0.7) interval with a genomewide significantly associated SNP(s) for hip geometry were taken forward for replication. Meta-analysis of the replication results was conducted by three collaborating centers (Broad Institute, Hebrew SeniorLife, Boston, MA, USA; and Ioannina, Greece). A fixed-effects model was used for meta-analysis of studies in the replication set and also in the final combined analyses of the discovery and replication sets, for each phenotype. Replication was proclaimed for any SNP when in the combined (joint) meta-analysis, (i)

GWS threshold was achieved and (ii) combined analysis p value was lower than that in the Discovery.

In silico search for independent signals (conditional analyses, Discovery stage)—To identify secondary (independent) association signals in the regions containing SNPs that were genome-wide significant, we performed region-wide association analyses conditioning on the most significant hip-geometry SNP within a 1 megabase (Mb) window of the SNP with the lowest p value in a given locus, by including the other SNPs as a covariate in the regression models.

In silico search for height-associated SNPs, BMD-associated SNPs, and any type of fracture GWAS (Discovery stage)—In order to test for independence between the hip geometry and adult height signals, we looked up SNPs at least suggestively associated ($p < 5 \times 10^{-6}$) in our Discovery analysis, in the dataset of SNPs associated with height in the Genetic Investigation of ANthropometric Traits (GIANT) Consortium meta-analysis of 183,727 subjects.⁽²⁵⁾ Furthermore, in order to determine if our GWS SNPs for hip geometry phenotypes were co-localized with previously identified SNPs for BMD, we looked up nearby “BMD SNPs.”⁽³¹⁾ To assess the potential relevance of discovered loci to fracture risk, we looked up hip-geometry SNP associations (SNPs that were at least suggestively associated in our discovery analysis with one of the four hip geometry phenotypes, adjusted for covariates) with fracture using a large study from the GEFOS consortium (37,857 cases and 227,116 controls).^(32,33)

LD score regression: SNP heritability and genetic correlations

LD score regression was used to estimate the SNP heritability (h^2) of the studied traits and to estimate the genetic correlation (r_g) (i) between hip geometry phenotypes and (ii) between hip geometry phenotypes and 235 traits and diseases with publicly available summary GWAS data using LD Hub.⁽³⁴⁾ This tool is a centralized database of summary-level GWAS results for hundreds of diseases/traits, as well as a Web interface that automates the LD score regression analysis pipeline.⁽³⁵⁾ To correct for multiple testing the r_g was deemed significant at $\alpha = 0.0002$ ($0.05/235$, Bonferroni-corrected for 235 tests).

Bioinformatic annotations and functional validation

Annotation of SNPs used NCBI's dbSNP build hg19.

Gene expression analysis in human bone

Global gene expression profiling was performed in transiliac bone biopsies obtained from postmenopausal white women from Oslo, as described.⁽³⁶⁾ This permitted us to calculate the correlation values between hip geometry SNPs (and their proxies) and the transcript levels of genes in the vicinity of the identified loci. In brief, the women undergoing bone biopsies (50 to 86 years old) were free from diseases other than osteoporosis or receiving medication (past or present) possibly affecting bone remodeling or representing secondary causes of osteoporosis.^(36,37) RNA was purified and analyzed using Affymetrix HG U133 2.0 plus arrays as described.⁽³⁶⁾ Bone total RNA was subjected to global transcript profiling using HG-U133 plus 2.0 microarrays (Affymetrix). These data are available at the European

Bioinformatics Institute (EMBL-EBI) ArrayExpress repository, ID: E-MEXP-1618 (<http://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-1618/>).^(17,38) DXA scans from the bone donors were subjected to HSA. Filtered transcript levels from 80 bone biopsies were correlated with hip geometry data; results were adjusted for multiple testing using false-discovery rate (FDR).

***cis*-Expression quantitative trait loci in human bone tissues**

Genomewide genotyping in the sample of women from Oslo was performed by Affymetrix Genome-Wide Human SNP Array 6.0/Affymetrix Axiom Biobank array (1,000,000 and 700,000 SNPs assessed, respectively).⁽³⁷⁾ We conducted *cis*-expression quantitative trait loci (*cis*-eQTLs) analysis within a 2-Mb flanking region (1 Mb upstream and 1 Mb downstream) of each of the replicated SNPs to evaluate whether they influence transcript levels of genes in human whole bone (using the same resource of iliac bone biopsies from 80 postmenopausal women).^(17,38)

Gene expression in primary murine osteoblasts and osteoclasts

Gene expression profiles (“Trajectories”, ie, increase or decrease within the days post-differentiation) of candidate genes in close proximity to genomewide associated SNPs were examined in primary mouse osteoblasts undergoing differentiation. These data have been described in detail⁽³⁹⁾ and are publicly available from the Gene Expression Omnibus (GSE54461). For details, see the Supporting Methods.

We also mined publically-available osteoclast expression data (GEO Accession GSM1873361; <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72846>) for expression (presence/absence) of candidate genes during osteoclastogenesis.

Coexpression network from mouse cortical bone

We used a coexpression network constructed from mouse cortical bone expression profiles.⁽⁴⁰⁾ By mapping mouse homologs of human genes located in GWAS regions associated with BMD, the network previously identified an Osteoblast Functional Module containing 33 genes implicated by GWAS.⁽⁴⁰⁾ For the association with hip geometry phenotypes, the following algorithm was applied:

- Step 1:** Using *plink2*, we generated LD intervals based on LD data from 1000 Genomes Phase I. The interval was defined by the upstream-most and downstream-most SNP in LD with the index SNP at an r^2 threshold of 0.7, as described in Calabrese and colleagues.⁽⁴⁰⁾ This resulted in the file “*plink.ld*” that contains all the proxies for the index SNPs based on build hg19.
- Step 2:** To define the set of genes mapped to the intervals, we converted the hg19 LD intervals defined in step one to hg38 intervals using the UCSC lift-over tool. A total of 12 unique genes were identified for the 5 (GWAS Discovery) regions.
- Step 3:** We then identified mouse homologs for all 12 unique human genes and mapped these onto the bone coexpression network.⁽⁴⁰⁾

Assay for transposase-accessible chromatin followed by sequencing epigenetic intersection analyses

We used two functional epigenomic datasets derived using the Assay for Transposase-Accessible Chromatin followed by sequencing (ATAC-seq) on embryonic day (E) 15.5 mouse proximal femora: (i) proximal femur (head+neck+proximal femur growth plate up to but not including the osseous diaphysis) ATAC-seq dataset, which consists of 24,804 called peaks ($n = 2$ biological replicates)⁽⁴¹⁾ and (ii) proximal femoral head ATAC-seq dataset, which consists of 22,727 called peaks (three biological replicates, unpublished). ATAC-seq assays and computational pipelines were performed as described in Guo and colleagues.⁽⁴²⁾ For both types of samples, we used stringent ENCODE recommended IDR (irreproducible discovery rate) cutoff of 0.05. Raw sequencing *fastq* files and processed peak *bed* files were previously deposited on NCBI GEO (GSE100585).

To perform computational intersections of these ATAC-seq datasets with height-adjusted hip-geometry-associated loci, *Mus musculus* (mm10) peak calls were first lifted over to the UCSC Genome Browser human genome (hg19). Second, we focused on the top five significant loci (Table 1), and for each lead (index) SNP we used the Broad Institute HaploReg v.4.1 tool⁽⁴³⁾ to identify all hg19 variants with an $r^2 \geq 0.4$ in the European 1000 Genomes Population dataset. This yielded 513 height adjusted hip geometry variants that could serve as linked, putatively causal variants. Third, we used BEDTools v2.18⁽⁴⁴⁾ and the UCSC Genome Table Browser tool⁽⁴⁵⁾ to identify any overlap (≥ 1 bp) of a height adjusted hip geometry variant and an ATAC-seq peak. Fourth, for loci showing intersections, we used Mouse Genome Informatics to identify expression patterns for nearby genes, when appropriate.

Results

Each participating study analyzed hip geometry phenotypes by GWAS using standard best practices (see Methods). A meta-analysis of the individual GWASs was performed first on the first set of studies with available GWAS results. The meta-analysis QQ plots did not provide evidence of genomic inflation of association test statistics (λ 's ranging from 1.01 to 1.07, (Supporting Table 3). Results of SNP–phenotype associations (hip geometry phenotype, top associated SNPs, their MAF, and functional impact) are presented in Table 1. Thus, the discovery analysis identified five loci with genomewide significant associations, in *IRX1/ADAMTS16* and near *FGFR4*, *NSDI*, and *RAB24* (chr. 5), a gene-dense region (*LRP5/PPP6R3/GAL*) on chr. 11, *CCDC91* (chr. 12), and *RUNX1* (chr. 21). The identified signals were either intronic or intergenic. Most of the loci were phenotype-specific. The chromosome region-wide association analyses with conditioning on the most significant SNP did not reveal secondary (independent) association signals.

The in silico replication was performed in the cohorts with existing GWAS, followed by the combined (joint) analysis of the Discovery and Replication stages. Thus, in the combined Discovery and Replication analysis, SNPs near *IRX1/ADAMTS16* (chr. 5), a gene-dense region (*LRP5/PPP6R3/GAL*) on chr. 11, and *CCDC91* (chr. 12) became GWS. SNP rs6556301 near *FGFR4*, *NSDI*, and *RAB24* (chr. 5), although still meeting the GWS

threshold, became slightly less significant than that in the Discovery ($p = 2.3 \times 10^{-8}$ and 1.4×10^{-8} , respectively). SNPs in *RUNX1* (chr. 21) did not replicate.

Some of the hip geometry-associated regions had previously been associated with DXA BMD (GEFOS Consortium, Table 2). Indeed, there were several signals overlapping with BMD at the suggestive level of significance ($p < 5 \times 10^{-6}$), mostly for narrow-neck section modulus phenotype: in/near *LRP5* (chr. 11). We further compared the hip-geometry-associated regions discovered by us with GWAS meta-analysis for height performed by the GIANT Consortium⁽²⁵⁾ (Table 3). Only rs11049605 in *CCDC91* (chr. 12) was GWS-associated with height.

We also looked up the SNPs that were suggestively ($p < 5 \times 10^{-6}$) associated with hip geometry in our Discovery analysis in the recent large GWAS of any type of fracture.⁽³²⁾ No SNP was nominally-significantly associated with fracture at $p < 0.05$ (Table 4).

Genetic correlations with hip geometry by LD score regression

LD score regression (Supporting Table 4) estimated that SNPs nominally associated with hip geometry phenotypes explained from $12.1 \pm 2.7\%$ heritability (NSA) and $12.9 \pm 3.3\%$ (FNL) to $17.5 \pm 2.9\%$ (NNZ) to $22.0 \pm 3.2\%$ of NN width. NNZ and NN width significantly correlated (0.369 ± 0.095 , $p < 0.001$), whereas FNL and NSA negatively correlated (-0.526 ± 0.179 , $p < 0.01$). We next determined the genetic correlations between hip geometry phenotypes and several traits and diseases (Supporting Table 5). Only other DXA-derived traits, including femoral, lumbar spine, and forearm BMD, demonstrated strong genetic correlation with NNZ (positive) or NNW (negative), at Bonferroni-corrected α threshold.

Gene expression analysis in human bone

We correlated hip geometry phenotypes with gene expression from human transiliac bone biopsies (Table 5). A total of 102 different transcripts were correlated with the various structural parameters at 10% FDR. Among Physiological System Development and Function categories the most significant were: “Connective Tissue Development and Function” (4.62×10^{-2} to 3.12×10^{-4}); “Embryonic Development” (4.63×10^{-2} to 3.12×10^{-4}), “Organ Development” (4.63×10^{-2} to 3.12×10^{-4}); “Organismal Development” (4.93×10^{-2} to 3.12×10^{-4}); “Skeletal and Muscular System Development and Function” (4.96×10^{-2} to 3.12×10^{-4}). Notably, several bone structure relevant subcategories (containing at least two genes) were identified within these categories, including: “Development of vertebral body” (CLEC3B), $p = 3.12 \times 10^{-4}$; “Differentiation of connective tissue cells” (IL1A, LRP8, MRPS18B, NIPBL, PIAS1, SOST, TOB1), $p = 8.67 \times 10^{-3}$; “Quantity of osteoclasts” (IL1A, SOST, TOB1), $p = 1.43 \times 10^{-2}$; “Ossification of bone” (NIPBL, SOST, TOB1), $p = 2.42 \times 10^{-2}$.

cis-eQTLs in Human Bone Tissues

The results of the *cis*-eQTL obtained from whole-bone biopsies are shown in Table 6. For genomewide significant SNPs we found two significant eQTLs after multiple testing correction (adjusted for number of SNP-gene pairs by Bonferroni correction), namely rs7102273 (intergenic, chr. 11) and *PPP6R3* (protein phosphatase 6 regulatory subunit 3)

expression ($p = 0.0007$), and rs6556301 (intergenic, chr. 5) and *PDLIM7* (PDZ and LIM domain 7) expression ($p = 0.005$).

Primary murine cells

We tested whether mouse homologs of human genes were expressed in mouse calvarial osteoblasts and found that for some, the expression changed during cell differentiation. Table 7 presents a list of genes whose expression profiles (trajectories) underwent changes. Thus, *Lrp5* expression increased with osteoblast differentiation; *Rab24* expression slightly decreased; *Irx1* expression increased and then reached a plateau at the late differentiation stage. Expression profiles for other genes were less obvious.

We also mined osteoclast expression data (GEO Accession GSM1873361; <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72846>) and found evidence of expression of some of our genes of interest in control mice in mature osteoclasts. On chr. 5 (proximal locus), *Adams16* expression, but not *Irx1*, was present during osteoclastogenesis; in distal locus on chr. 5, among the three genes of interest, expression of *Rab24* and *Nsd1* was detected but reads mapping to *Fgfr4*, were not observed in mature osteoclasts suggesting a lack of expression of this gene in these cells. On chr. 11, notably *Lrp5* and *Ppp6r3* were expressed in osteoclasts whereas *Gal* was not.

Coexpression network from mouse cortical bone expression profiles

We previously used a network-based approach to nominate potentially causal genes at BMD GWAS associations.⁽⁴⁰⁾ In this work, Calabrese and colleagues⁽⁴⁰⁾ identified two modules from a bone coexpression network that were enriched for genes implicated by BMD GWAS. For the hip geometry GWAS results we determined if implicated genes were members of these two modules (referred to as modules 6 and 9). We hypothesized that genes implicated by hip geometry GWAS and members of modules 6/9 might play a role in the regulation of hip geometry and be strong candidates to underlie associations with hip geometry.

A total of 12 genes were identified for the five GWAS regions and all 12 had clear mouse homologs. Two (*LRP5* and *PPP6R3*) of the 12 mouse genes belonged to either module 6 and or 9. Both of these modules have previously been shown to be enriched for genes with well-known roles in osteoblast activity.

ATAC-seq epigenomic intersections in mice

We performed computational intersections between two ATAC-seq datasets derived from mouse embryonic proximal femora (see Methods) and 513 height-adjusted hip-geometry variants from five associated loci to identify putative regulatory variants influencing proximal femur geometry. Our intersections with a first dataset derived from all proximal femur tissues revealed five hip geometry variants from two loci that overlap with an ATAC-seq peak (Supporting Table 6). At the *IRX1/ADAMTS16* locus on chr. 5, four variants fell within the same ATAC-seq peak, with rs6871994 in the strongest LD to lead variant ($r^2 = 0.88$) and associated with FNL. At the *RUNX1* locus on chr. 21, rs8129061 is at $r^2 = 0.51$ to the lead variant, resides within an ATAC-seq peak within a gene desert, and is associated with FNL. Intersections with a second dataset, focused specifically on the proximal femoral

head cartilage, did not yield any SNPs. All remaining loci (including *FGFR4*, *NSD1*, *RAB24*, *LRP5*, *PPP6R3*, *GAL*, and *CCDC91*) did not yield variant intersections with either dataset, although ATAC-seq peaks were identified in the vicinity of each gene (Supporting Fig. 2).

Discussion

This is the largest study to comprehensively assess genetic variants associated with proximal femur geometry using a GWAS approach with functional validation in human bone transcript profiles, cell, and animal data. Despite the contribution of bone geometry of the femur to fracture risk,⁽¹¹⁾ and the known heritability of hip geometry traits measured using HSA (28% to 70%⁽¹²⁾), there have been no large-scale GWASs for hip geometry. We assessed the evidence of association of the novel markers identified here, in large GWAS meta-analyses of height (183,727 participants⁽²⁵⁾), DXA-derived lumbar spine ($n \cong 32,000$) and femoral neck BMD ($n \cong 32,000$)⁽²⁰⁾ as well as fracture (37,857 cases and 227,116 controls from the GEFOS consortium).

Our GWAS findings identified several noteworthy genes. In the combined discovery and replication meta-analysis, significant associations were found for *FNL* at 5p15 where *IRX1* and *ADAMTS16* are mapped ($p = 2.4 \times 10^{-8}$). In height-adjusted NNW, significant association was observed at 12p11 ($p = 4.9 \times 10^{-12}$) in the intron of *CCDC91*. Height-adjusted NNZ was associated with variants at 11q13 near *LRP5* and *PPP6R3* ($p = 4.3 \times 10^{-11}$), which are known genes for BMD. SNPs in *FGFR4/NSD1/RAB24* (chr. 5) and in *RUNX1* (chr. 21) did not replicate. It is of interest that *FGFR4* interacts with *FGF23*, an inhibitor of mineralization; and *RUNX1* is involved in hematopoiesis and osteogenesis.

Because stature is an important contributor to hip fracture, and because measures of hip geometry are dependent on an individual's size, we performed a systematic study of the genetic associations of hip geometry with adjustment for height, in a sample of >27,000 adults. Importantly, we performed GWAS of hip geometry with adjustment for height at a whole-genome scale, not only for the subset of SNPs previously shown to be associated with height (to prevent "collider bias"⁽⁴⁵⁾). We did not adjust our hip geometry measures for areal BMD because these measures are both DXA-derived (therefore "collider bias"⁽⁴⁵⁾ might be expected). We also performed non-height-adjusted analysis (not shown here). The following chromosomal loci/genes were identified at suggestive-GWS levels: *HHIP* (chr. 4), *ENPP2* (on chr. 8), *ASTN2/TMEM38B* (chr. 9), near *FAM10A4/DLEU2* (chr. 13), *GDF5* and *DDX27* (both on chr. 20). Not surprising, SNPs in most of these genes were also strongly associated with adult height. Of note, in our height-adjusted analysis, only rs11049605 in *CCDC91* (chr. 12) was still GWS-associated with height, therefore indicating that adjustment for height dramatically reduced hip geometry associated signals, probably due to body-size contribution to the HG phenotypes.

Of note, one previous GWAS in 1000 European-descent Americans⁽¹⁶⁾ found a common genetic variant, rs7430431 in the receptor transporting protein 3 (*RTP3*) gene, to be in strong association with the buckling ratio ($p = 1.6 \times 10^{-7}$), an index of bone structural instability,

and with femoral cortical thickness ($p = 1.9 \times 10^{-6}$). The *RTP3* gene is located at 3p21.31. We were unable to confirm this signal in our much larger study.

We further looked for shared associations between our hip geometry phenotypes and bone fractures. SNP rs7102273 (intergenic, 11q13.2) was associated with fracture ($p = 7.5 \times 10^{-5}$); the allele that was associated with higher NNZ, also corresponded to the lower risk of fracture. Of interest, this SNP is in LD ($R^2 = 0.96$; $D' = 1$) with another intronic variant, rs12272917, that was associated with skull BMD in Kemp and colleagues⁽⁴⁶⁾ study (the distance between the SNPs is ~122.2K). Both SNPs are in *PPP6R3* (a.k.a. *SAPS3*) gene, whose Gene Ontology (GO) annotations include “protein phosphatase binding,” and related pathways are “Transport to the Golgi and subsequent modification” and “Vesicle-mediated transport.” It is still unclear how the gene may be influencing bone geometry. Some of our signals fall into known loci for other bone phenotypes. Apart from *LRP5* and *PPP6R3* (chr. 11) there were no signals overlapping with BMD at the suggestive level of significance ($p < 5 \times 10^{-6}$).

By correlating hip geometry phenotypes with gene expression from transiliac bone biopsies, we found gene transcripts falling into several functional categories. Among “Physiological System Development and Function” categories the most significant were “Connective Tissue Development and Function,” “Embryonic Development,” “Organ Development,” “Organismal Development,” and “Skeletal and Muscular System Development and Function.” Notably, several bone structure relevant subcategories (containing at least two genes) were identified within these categories, including: “Development of vertebral body,” “Differentiation of connective tissue cells,” “Quantity of osteoclasts,” and “Ossification of bone,” supporting the bone-structure role of the genes associated with hip geometry.

To further understand functional implications of our hip geometry signals via molecular and cellular mechanisms, we used the bone coexpression network from prior work of Calabrese and colleagues.⁽⁴⁰⁾ They found that mouse analogues of BMD GWAS genes were enriched for genes important to bone (mostly osteoblast) biology. By mapping mouse homologs of human genes located in GWAS regions onto murine dataset, they identified an Osteoblast Functional Module containing 33 genes implicated by GWAS. These genes are candidates for 30 of the 64 BMD GWAS regions discovered by GEFOS in European-descent persons.⁽⁴⁷⁾ Most of the GO ontologies shared between these modules corresponded to cellular components, biological processes, and molecular functions pertinent to osteoblasts and ossification.^(40,48) The top genes for hip geometry included *PPP6R3* and *LRP5*, whose expression correlated with osteoblastic modules. We thus suggest that the identification of our GWAS top SNPs for hip geometry confirms they are excellent candidates for being potentially responsible for the signal in associated loci.

Given that greater than 95% of variants (ie, those with $r^2 > 0.4$ to lead hip-geometry-associated variants) fall within noncoding regions, they likely function to alter hip geometry through their effects on gene regulation. To refine the putative functional roles of hip geometry variants in this context and in the absence of inaccessible human developmental tissues, we performed computational intersections of all such variants with ATAC-seq datasets derived from embryonic mouse chondrocytes, at a stage when proximal femoral

morphology is initially determined. These analyses yielded two associated novel loci with five variants in strong to modest LD with the lead variant within an ATAC-seq peak. We detected variants in distant-acting enhancers at two loci associated with FNL (*IRX1//ADAMTS16* and *RUNX1*). Although mouse and/or human chondrocyte or bone phenotypes have only been reported for *Runx1//RUNX1*,⁽⁴⁹⁾ IRX1 has been shown to influence chondrocyte differentiation⁽⁵⁰⁾ and it (MGI⁽⁵¹⁾), along with *Adamts16* (MGI⁽⁵²⁾) and *Runx1* (MGI⁽⁵³⁾) is expressed during mouse femoral development. Although follow-up experiments on variants in *IRX1* could further demonstrate its role in hip geometry, its re-identification here bolsters our computational strategy to whittle down loci to fewer putatively causal variants.

We also mined two publicly available datasets, of primary mouse osteoblasts undergoing differentiation (GSE54461) and osteoclast expression data (GSM1873361). In mouse primary cells, among chr. 11 genes, *Lrp5* (but not *Ppp6r3*) expression increased with osteoblast differentiation. For both *Lrp5* and *Ppp6r3*, expression was present during osteoclastogenesis, whereas *Gal* was not expressed in either osteoblasts or osteoclasts. This evidence supports the role that *LRP5*, a well-known bone-active gene, plays in “pleiotropic” actions on most bone-related properties.

We then interrogated a unique dataset of global gene expression from transiliac bone biopsies obtained from 84 postmenopausal women.⁽³⁶⁾ In human whole bone biopsies, transcripts for *LRP5* correlated with FNL of the biopsied persons ($p < 0.05$), whereas transcripts for *RUNX1* correlated with their NNZ ($p < 0.05$). Finding the associations with *LRP5* confirm earlier results of Wnt signaling system’s candidates associated with BMD and fracture risk.⁽³⁶⁾ Validation of our top genes detected in human bone samples by RT-PCR was carried out previously.^(36,54)

Because most of these postmenopausal women with transiliac bone biopsies were genotyped, eQTLs were also available for our analysis. Thus, for subset of SNPs we found two eQTLs, still significant after applying multiple testing correction (by FDR), namely rs7102273 (intergenic, chr. 11) to associate with *PPP6R3* expression ($p = 0.0007$), and rs6556301 (intergenic, chr. 5) with *PDLIM7* expression ($p = 0.005$). *PDLIM7* (PDZ and LIM Domain 7/ Enigma) is known to code for the LIM mineralization proteins (LMP), which have an important osteogenic role.⁽⁵⁵⁾ It seems that alteration of gene expression by the variants located in a regulatory region in the vicinity of *PPP6R3*, similar to *PDLIM7*, may affect bone geometry. We did not observe a link between the associated SNPs in the chr. 11 region and *LRP5* gene expression in human bones. The low expression level in whole bone and small sample size in human eQTL studies may limit the statistical power to detect *cis*-eQTLs.

We also estimated that SNPs associated with hip geometry phenotypes explained from 12.1 ± 2.7 heritability in NSA up to 22.0 ± 3.2 (NN width). NN section modulus and NN width significantly correlated (0.369 ± 0.095 , $p < 0.001$), whereas FNL and NSA negatively correlated (-0.526 ± 0.179 , $p < 0.01$). It is important to note that due to our relatively modest sample ($n = 18,719$), many more SNPs are expected to be uncovered through larger efforts, as follows from our experience with GWAS of other phenotypes, namely BMD,

height, and BMI, which will explain larger portion of heritability. Moreover, only singular signals (loci) generally reached GWS for each hip geometry trait: two for each FNL and NNW, one for NNZ, and none for NSA (Discovery). The impact of a single variant on a complex polygenic trait is usually small, and multiple variants with small effects, operating within a complex network, likely underlie hip geometry variance. Therefore, identification of a larger number of gene variants that play a role in bone architecture is necessary before real gains in predicting fracture risk can be achieved by using hip-geometry-associated variants. Statistical evidence (replication in independent cohorts) and biological evidence (from mammalian cells and human whole bone), although not always agree, are both indispensable for finding the true genetic loci.

The primary advantage of HSA-measured hip geometry is that bone geometry and areal BMD, both of which contribute to bone strength, are considered. This, however, makes our task of distinguishing between genetics of hip geometry per se, independent of BMD, challenging. It is important to emphasize that hip geometry is actually measured from the DXA image data, not estimated via the BMD. The algorithm of HSA was described in detail in Beck and Broy.⁽⁵⁶⁾ Of note, we found genetic correlations between some hip geometry phenotypes and DXA-derived BMD at femur, lumbar spine, and forearm. These genetic correlations were positive with NN-section modulus (bone strength measure) but negative with NN-width. The latter fully complies with the understanding that wider bones have larger cross-sectional area but not necessary higher density; this underlines the potential role of expansion of outer femoral neck diameter and cortical thinning that occurs with aging.⁽¹¹⁾ The oldest women had wider femoral necks containing less bone tissue, thinner cortices, less bending resistance, and significantly greater buckling ratios.⁽⁵⁷⁾

This study has several limitations that need to be noted. GWAS studies were imputed to older imputation panels because the initial imputation began at the early stages of this project several years ago; at the present, newer and denser panels exist (1000Genomes, HRC and UK10K). More detailed exploration would need fine-mapping and sequencing of the loci prioritized here. Also, animal modeling experiments were considered beyond the scope of the present study. Given the biologic plausibility of our findings, further exploration is left to future studies.

In conclusion, our GWAS-based study provides indications that hip geometry measured using HSA may reveal novel molecular pathways influencing skeletal shape and impacting mechanical properties. Our findings also suggest that HAS-measured hip geometry might capture additional genetic determinants beyond those associated with hip BMD. These variants should be prioritized for future functional validation regarding their involvement in the regulation of bone strength and risk of hip fracture. At the current stage of genetics research, there are few instances where genetic association findings are directly used clinically. However, because hip geometry contributes to hip fracture risk,⁽²⁾ discovery of genetic determinants of hip geometry may have utility in predicting fracture as methods to derive polygenic risk scores mature further.^(3,4) Because hip geometry still evolves in early life and even beyond, the identification of genetic determinants of hip architecture could be used as potential diagnostic tools and drug targets to improve bone strength.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Yi-Hsiang Hsu^{1,2,3}, Karol Estrada^{3,4,5,*}, Evangelos Evangelou^{6,*}, Cheryl Ackert-Bicknell⁷, Kristina Akesson^{8,9}, Thomas Beck¹⁰, Suzanne J Brown¹¹, Terence Capellini¹², Laura Carbone¹³, Jane Cauley¹⁴, Ching-Lung Cheung¹⁵, Steven R Cummings¹⁶, Stefan Czerwinski¹⁷, Serkalem Demissie¹⁸, Michael Econs¹⁹, Daniel Evans¹⁶, Charles Farber²⁰, Kaare Gautvik²¹, Tamara Harris²², Candace Kammerer¹⁴, John Kemp^{23,24}, Daniel L Koller¹⁹, Annie Kung¹⁵, Debbie Lawlor²⁴, Miryoung Lee¹⁷, Mattias Lorentzon²⁵, Fiona McGuigan^{7,8}, Carolina Medina-Gomez⁵, Braxton Mitchell²⁶, Anne Newman¹⁴, Carrie Nielson²⁷, Claes Ohlsson²⁸, Munro Peacock¹⁹, Sjur Reppe^{21,29}, J Brent Richards³⁰, John Robbins³¹, Gunnar Sigurdsson³², Timothy D Spector³³, Kari Stefansson³⁴, Elizabeth Streeten²⁶, Unnur Styrkarsdottir³⁴, Jonathan Tobias³⁵, Katerina Trajanoska⁵, André Uitterlinden^{4,5}, Liesbeth Vandenput²⁸, Scott G Wilson^{11,33,36}, Laura Yerges-Armstrong³⁷, Mariel Young¹², Carola Zillikens^{4,5}, Fernando Rivadeneira^{4,5}, Douglas P Kiel^{1,2,3}, David Karasik^{1,38}

Affiliations

¹Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA ²Harvard Medical School, Boston, MA ³Broad Institute, Cambridge, MA ⁴Department of Internal Medicine, Erasmus MC, 3000 CA Rotterdam, the Netherlands ⁵Department of Epidemiology, Erasmus MC, 3000 CA Rotterdam, the Netherlands ⁶Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina 45110, Greece ⁷Center for Musculoskeletal Research, Department of Orthopaedics, University of Rochester, Rochester, New York, USA ⁸Department of Clinical Sciences Malmö, Lund University, Sweden ⁹Department of Orthopedics, Skåne University Hospital, S-205 02 Malmö, Sweden ¹⁰Beck Radiological Innovations, Baltimore, MD ¹¹Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Australia ¹²Department of Human Evolutionary Biology, Harvard University, Cambridge, MA ¹³Department of Medicine at the Medical College of Georgia at Augusta University, Augusta, GA ¹⁴Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA ¹⁵Department of Medicine, The University of Hong Kong, Hong Kong, China ¹⁶California Pacific Medical Center Research Institute, San Francisco, CA ¹⁷University of Texas, School of Public Health at Bronwsville, TX ¹⁸Department of Biostatistics, Boston University School of Public Health, Boston, MA ¹⁹Department of Medicine and Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN ²⁰Public Health Sciences, University of Virginia, Charlottesville, VA ²¹Lovisenberg Diakonale Hospital, Unger-Vetlesen Institute, and University of Oslo, Institute of Basic Medical Sciences, Oslo, Norway ²²Laboratory of Epidemiology and Population Sciences, Intramural Research Program, NIA, Bethesda, MD ²³University of Queensland Diamantina

Institute, Translational Research Institute, Brisbane, Queensland, Australia ²⁴MRC Integrative Epidemiology Unit, University of Bristol, UK ²⁵Department of Internal Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden ²⁶Program in Personalized and Genomic Medicine, and Department of Medicine, Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, and Geriatric Research and Education Clinical Center - Veterans Administration Medical Center, Baltimore, MD ²⁷Oregon Health & Science University, Portland, OR ²⁸Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, SE-413 45 Gothenburg, Sweden ²⁹Oslo University Hospital, Department of Medical Biochemistry, Oslo, Norway ³⁰Department of Human Genetics, McGill University, and Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada ³¹Department of Medicine, University California at Davis, Sacramento, CA ³²Faculty of Medicine, University of Iceland, Reykjavík, Iceland ³³Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Campus, London, UK ³⁴deCODE Genetics, 101 Reykjavik, Iceland ³⁵Musculoskeletal Research Unit, University of Bristol, UK ³⁶School of Biomedical Sciences, University of Western Australia, Nedlands, Australia ³⁷Genetics, GlaxoSmithKline, King of Prussia, PA ³⁸The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel

Acknowledgments

Discovery Cohorts

Old Order Amish (OOA): This work was supported by NIH research grant R01 AR046838. Partial funding was also provided by the Mid-Atlantic Nutrition and Obesity Research Center of Maryland (P30 DK072488). LMYA was supported by F32AR059469 from NIH/NIAMS. MF was supported by American Heart Association grant [10SDG2690004].

Cardiovascular Health Study (CHS): This CHS research was supported by NHLBI contracts N01-HC- 85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086; N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133, N01-HC-85239, and by HHSN268201200036C and NHLBI grants HL080295, HL087652, HL105756, HL103612, HL130114 with additional contribution from NINDS. Additional support was provided through AG-023629, AG-15928, AG-20098, and AG-027058 from the NIA. See also <http://www.chs-nhlbi.org/pi.htm>. DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by the National Center for Research Resources, grant UL1RR033176, and is now at the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881; in addition to the National Institute of Diabetes and Digestive and Kidney Disease grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

Framingham Osteoporosis Study (FOS): The study was funded by grants from the US National Institute for Arthritis, Musculoskeletal and Skin Diseases and National Institute on Aging (R01 AR41398 and U24AG051129; DPK and R01 AR057118, R01 AR061162, R01 AR050066, and R01 AR061445). DK was also supported by Israel Science Foundation grant #1283/14. The Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health and Boston University School of Medicine were supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (N01-HC-25195) and its contract with Affymetrix, Inc. for genotyping services (N02-HL-6-4278). Analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. A portion of this research was conducted using the Linux Cluster for Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. eQTL HOB Study: The study was supported by Genome Quebec, Genome Canada and the Canadian Institutes of Health Research (CIHR).

Gothenburg Osteoporosis and Obesity Determinants Study (GOOD): The study was funded by the Swedish Research Council, the Swedish Foundation for Strategic Research, The ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Emil and Vera Cornell Foundation, the Torsten and Ragnar Söderberg's Foundation, Petrus and Augusta Hedlunds Foundation, the Västra Götaland Foundation, and the Göteborg Medical Society. We would like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technology under grants #01 AK 803 A-H and # 01 IG 07015 G for access to their grid resources.

Health Aging and Body Composition Study (Health ABC): This study was funded by the National Institutes of Aging. This research was supported by NIA contracts N01AG62101, N01AG62103, and N01AG62106. The genome-wide association study was funded by NIA grant 1R01AG032098-01A1 to Wake Forest University Health Sciences and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C.

Indiana: We thank the individuals who participated in this study, as well as the study coordinators, without whom this work would not have been possible. This work was supported by National Institutes of Health grants R01 AG041517 and 5UL1TR001108. Genotyping services were provided by CIDR. CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN268200782096C. This research was supported in part by the Intramural Research Program of the NIH, National Library of Medicine.

Rotterdam Study (RSI, RSII, & RSIII): The generation and management of GWAS genotype data for the Rotterdam Study (RS I, RS II, RS III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organisation of Scientific Research NWO Investments (nr. 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project nr. 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera and Marjolein Peters, for their help in creating the GWAS database, and Yurii Aulchenko, PhD, for the creation of imputed data. We would like to thank Dr. Tobias A. Knoch, Marijn Verkerk, Anis Abuseiris, Dr. Linda Boer and Rob de Graaf (Erasmus MC Rotterdam, The Netherlands), for their help in creating and maintaining GRIMP. Dr. Fernando Rivadeneira received an additional grant from the Netherlands Organization for Health Research and Development ZonMw VIDI 016.136.367. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are very grateful to the study participants, the staff from the Rotterdam Study (particularly L. Buist and J.H. van den Boogert) and the participating general practitioners and pharmacists.

Twins UK (TUK): The study was funded by the Wellcome Trust, the Arthritis Research UK, the Chronic Disease Research Foundation, the Canadian Institutes of Health Research (J.B.R.), the European Society for Clinical and Economic Aspects of Osteoporosis (J.B.R.) and the European Union FP-5 GenomEUtwin Project (QLG2-CT-2002-01254). The study also received support from a National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London. We thank the staff of the Twins UK study; the DNA Collections and Genotyping Facilities at the Wellcome Trust Sanger Institute for sample preparation; Quality Control of the Twins UK cohort for genotyping (in particular A. Chaney, R. Ravindrarajah, D. Simpkin, C. Hinds and T. Dibling); P. Martin and S. Potter of the DNA and Genotyping Informatics teams for data handling; Le Centre National de Génotypage, France, led by M. Lathrop, for genotyping; Duke University, North Carolina, USA, led by D. Goldstein, for genotyping; and the Finnish Institute of Molecular Medicine, Finnish Genome Center, University of Helsinki, led by A. Palotie. The study was also supported by Israel Science Foundation, grant number #994/10 and the Australian National Health and Medical Research Council (NHMRC) (Project Grants 1048216, 1127156).

Replication Cohorts

ALSPAC: We are extremely grateful to all the families who took part in this study, the midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. ALSPAC data collection was supported by the Wellcome Trust (grants WT092830M; WT088806; WT102215/2/13/2), UK Medical Research Council (G1001357), and University of Bristol. The UK Medical Research Council and the Wellcome Trust (ref: 102215/2/13/2) and the University of Bristol provide core support for ALSPAC.

deCODE Study: The study was funded by deCODE Genetics, ehf. We thank all the participants of this study, the staff of deCODE Genetics core facilities and recruitment center and the densitometry clinic at the University Hospital for their important contributions to this work.

Fels Longitudinal Study (FELS): The study was supported by NIH research grants, R01 HD012252 and R01 AR052147. The authors are thankful to the Fels Longitudinal Study participants for their long-term commitment to the study and to data collection staff at the Department of Population and Public Health Sciences, Boonshoft School of Medicine, Wright State University.

Osteoporosis Prospective Risk Assessment study (OPRA): This work was supported by grants from the Swedish Research Council (K2015-52X-14691-13-4), Greta and Johan Kock Foundation, A. Pålsson Foundation, A. Osterlund Foundation, the H Järnhardt foundation, King Gustav V and Queen Victoria Foundation, Åke Wiberg Foundation, The Swedish Rheumatism Association, Skåne University Hospital Research Fund, Research and Development Council of Region Skåne, Sweden.

The authors are thankful to all the women who kindly participated in the study and to the staff at the Clinical and Molecular Osteoporosis Research Unit for helping in recruitment of study individuals.

Rotterdam II and III: Rotterdam Study (RS): See Discovery Cohort

SOF: The Study of Osteoporotic Fractures (SOF) is supported by National Institutes of Health funding. The National Institute on Aging (NIA) provides support under the following grant numbers: R01 AG005407, R01 AR35582, R01 AR35583, R01 AR35584, R01 AG005394, R01 AG027574, and R01 AG027576. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) provided funding for the SOF ancillary study "GWAS in mROS and SOF" under the grant number RC2ARO58973.

Functional Validation

We thank Dr. Claire Reardon and the entire Harvard University Bauer Core facility for assistance with next generation sequencing. This work was funded in part by the Harvard University Milton Fund, NSF (BCS-1518596), and NIH NIAMS (1R01AR070139-01A1) to TDC.

Functional validation in humans was supported by the South East Norway Health Authority (52009/8029), the 6th EU framework program (LSHM-CT-2003-502941), Oslo University Hospital, Ullevaal (52009/8029) and Lovisenberg Diakonale Hospital to KMG and SR.

References

1. Kendler DL, Bauer DC, Davison KS, et al. Vertebral fractures: clinical importance and management. *Am J Med.* 2016;129(2):221.e1-10.
2. Oudshoorn C, Hartholt KA, Zillikens MC, et al. Emergency department visits due to vertebral fractures in the Netherlands, 1986-2008: steep increase in the oldest old, strong association with falls. *Injury.* 2012;43(4):458-61. [PubMed: 22055140]
3. López-Delgado L, Riancho-Zarrabeitia L, Riancho JA. Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis. *Expert Opin Drug Metab Toxicol.* 2016;12(4):389-98. [PubMed: 26891809]
4. Leslie WD, Sadatsafavi M, Lix LM, et al. Secular decreases in fracture rates 1986-2006 for Manitoba, Canada: a population-based analysis. *Osteoporos Int.* 2011;22(7):2137-43. [PubMed: 21069292]
5. Amin S, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd. Trends in fracture incidence: a population-based study over 20 years. *J Bone Miner Res.* 2014;29(3):581-9. [PubMed: 23959594]
6. Ahlborg HG, Nguyen ND, Nguyen TV, Center JR, Eisman JA. Contribution of hip strength indices to hip fracture risk in elderly men and women. *J Bone Miner Res.* 2005;20(10):1820-7. [PubMed: 16160739]
7. Liu CT, Karasik D, Zhou Y, et al. Heritability of prevalent vertebral fracture and volumetric bone mineral density and geometry at the lumbar spine in three generations of the Framingham study. *J Bone Miner Res.* 2012;27(4):954-8. [PubMed: 22222934]
8. Leslie WD, Lix LM, Morin SN, et al. Adjusting hip fracture probability in men and women using hip axis length: the Manitoba Bone Density Database. *J Clin Densitom.* 2016;19(3):326-31. [PubMed: 26257267]

9. Leslie WD, Lix LM, Morin SN, et al. Hip axis length is a FRAX- and bone density-independent risk factor for hip fracture in women. *J Clin Endocrinol Metab.* 2015;100(5):2063–70. [PubMed: 25751108]
10. Richards JB, Zheng HF, Spector TD. Genetics of osteoporosis from genome-wide association studies: advances and challenges. *Nat Rev Genet.* 2012;13(8):576–88. [PubMed: 22805710]
11. Kaptoge S, Beck TJ, Reeve J, et al. Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. *J Bone Miner Res.* 2008;23(12):1892–904. [PubMed: 18684092]
12. Demissie S, Dupuis J, Cupples LA, Beck TJ, Kiel DP, Karasik D. Proximal hip geometry is linked to several chromosomal regions: genome-wide linkage results from the Framingham Osteoporosis Study. *Bone.* 2007;40(3):743–50. [PubMed: 17079199]
13. Cheung CL, Livshits G, Zhou Y, et al. Hip geometry variation is associated with bone mineralization pathway gene variants: the Framingham Study. *J Bone Miner Res.* 2010;25(7):1564–71. [PubMed: 19888898]
14. Anderson DE, Demissie S, Allaire BT, et al. The associations between QCT-based vertebral bone measurements and prevalent vertebral fractures depend on the spinal locations of both bone measurement and fracture. *Osteoporos Int.* 2014;25(2):559–66. [PubMed: 23925651]
15. Orwoll ES, Oviatt SK, Mann T. The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men. *J Clin Endocrinol Metab.* 1990;70(4):1202–7. [PubMed: 2318940]
16. Zhao LJ, Liu XG, Liu YZ, et al. Genome-wide association study for femoral neck bone geometry. *J Bone Miner Res.* 2010;25(2):320–9. [PubMed: 20175129]
17. Hsu YH, Zillikens MC, Wilson SG, et al. An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility loci for osteoporosis-related traits. *PLoS Genet.* 2010;6(6):e1000977. [PubMed: 20548944]
18. Kiel DP, Demissie S, Dupuis J, Lunetta KL, Murabito JM, Karasik D. Genome-wide association with bone mass and geometry in the Framingham Heart Study. *BMC Med Genet.* 2007; 8 Suppl 1:S14. [PubMed: 17903296]
19. Koller DL, Zheng HF, Karasik D, et al. Meta-analysis of genome-wide studies identifies WNT16 and ESR1 SNPs associated with bone mineral density in premenopausal women. *J Bone Miner Res.* 2013;28(3):547–58. [PubMed: 23074152]
20. Estrada K, Peters M, Hsu YH, et al. Genome-wide CNV association study identifies a rare deletion on chromosome 6p25 associated with osteoporotic fractures. [Presented at: Annual Meeting American Society of Human Genetics (ASHG); 2009 Oct 20–24; Honolulu, HI, USA; Presentation Number: 298]. Available from: <http://www.ashg.org/meetings/documents/2009-platformabstracts.pdf>.
21. Schraven SP, Franz C, Ruttiger L, et al. Altered phenotype of the vestibular organ in GLAST-1 null mice. *J Assoc Res Otolaryngol.* 2012;13(3):323–33. [PubMed: 22350511]
22. Courtland HW, Elis S, Wu Y, et al. Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner. *PLoS One.* 2011;6(3):e14762. [PubMed: 21445249]
23. Beck TJ, Ruff CB, Warden KE, Scott WW Jr, Rao GU. Predicting femoral neck strength from bone mineral data. A structural approach. *Invest Radiol.* 1990;25(1):6–18. [PubMed: 2298552]
24. Khoo BC, Beck TJ, Qiao QH, et al. In vivo short-term precision of hip structure analysis variables in comparison with bone mineral density using paired dual-energy X-ray absorptiometry scans from multicenter clinical trials. *Bone.* 2005;37(1):112–21. [PubMed: 15869917]
25. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. *Nature.* 2010;467(7317):832–8. [PubMed: 20881960]
26. Marchini J, Howie B, Myers S, McVean G, Donnelly P. A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet.* 2007;39(7):906–13. [PubMed: 17572673]
27. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. *Genet Epidemiol.* 2010;34(8):816–34. [PubMed: 21058334]

28. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics*. 2008;24(24):2938–9. [PubMed: 18974171]
29. Sudmant PH, Rausch T, Gardner EJ, et al. An integrated map of structural variation in 2,504 human genomes. *Nature*. 2015;526-(7571): 75–81. [PubMed: 26432246]
30. Pruim RJ, Welch RP, Sanna S, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010; 26(18):2336–7. [PubMed: 20634204]
31. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet*. 2012;44 <https://www.ncbi.nlm.nih.gov/pubmed/22504420>
32. Trajanoska K, Morris J, Oei L, et al. GEFOS/GENOMOS consortium and the 23andMe research team. Assessment of the genetic and clinical determinants of fracture risk: a Mendelian randomization approach. *BMJ*. 2018;362:k3225. [PubMed: 30158200]
33. Trajanoska K Leveraging genetic associations to evaluate clinical risk factors for osteoporotic fractures. *Calcif Tissue Int*. 2017;100 Suppl 1. [Presented at 44th European Calcified Tissue Society Congress (ECTS 2017); 2017 May 13–16; Salzburg, Austria]. DOI:10.1007/s00223-017-0267-2.
34. Zheng J, Erzurumluoglu AM, Elsworth BL, et al. LD Hub: a centralized database and web interface to perform LD score regression that maximizes the potential of summary level GWAS data for SNP heritability and genetic correlation analysis. *Bioinformatics*. 2017; 33(2):272–9. [PubMed: 27663502]
35. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J. Schizophrenia Working Group of the Psychiatric Genomics Consortium, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet*. 2015;47:291–5. [PubMed: 25642630]
36. Reppe S, Refvem H, Gautvik VT, et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women. *Bone*. 2010;46(3):604–12. [PubMed: 19922823]
37. Reppe S, Datta HK, Gautvik KM. Omics analysis of human bone to identify genes and molecular networks regulating skeletal remodeling in health and disease. *Bone*. 2017;101(Suppl C):88–95. [PubMed: 28450214]
38. Grundberg E, Brandstrom H, Lam KC, et al. Systematic assessment of the human osteoblast transcriptome in resting and induced primary cells. *Physiol Genomics*. 2008;33(3):301–11. [PubMed: 18334548]
39. Zheng HF, Forgetta V, Hsu YH, et al. Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. *Nature*. 2015;526(7571):112–7. [PubMed: 26367794]
40. Calabrese GM, Mesner LD, Stains JP, et al. Integrating GWAS and coexpression network data identifies bone mineral density genes SPTBN1 and MARK3 and an osteoblast functional module. *Cell Syst*. 2016;4(1):46–59.e4. [PubMed: 27866947]
41. Guo M, Liu Z, Willen J, et al. Epigenetic profiling of growth plate chondrocytes sheds insight into regulatory genetic variation influencing height. *Elife*. 2017;6: e29329. [PubMed: 29205154]
42. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res*. 2012;40(Database issue):D930–4. [PubMed: 22064851]
43. Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics*. 2010;26(6):841–2. [PubMed: 20110278]
44. Karolchik D, Hinrichs AS, Furey TS, et al. The UCSC Table Browser data retrieval tool. *Nucleic Acids Res*. 2004;32(Database issue):D493–6. [PubMed: 14681465]
45. Aschard H, Vilhjalmsdottir BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. *Am J Hum Genet*. 2015;96(2):329–39. [PubMed: 25640676]
46. Kemp JP, Medina-Gomez C, Estrada K, et al. Phenotypic dissection of bone mineral density reveals skeletal site specificity and facilitates the identification of novel loci in the genetic regulation of bone mass attainment. *PLoS Genet*. 2014;10(6):e1004423. [PubMed: 24945404]

47. Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. *Nat Genet.* 2012;44(5):491–501. [PubMed: 22504420]
48. Calabrese G, Bennett BJ, Orozco L, et al. Systems genetic analysis of osteoblast-lineage cells. *PLoS Genet.* 2012;8(12):e1003150. [PubMed: 23300464]
49. Kimura A, Inose H, Yano F, et al. Runx1 and Runx2 cooperate during sternal morphogenesis. *Development.* 2010;137(7):1159–67. [PubMed: 20181744]
50. Askary A, Mork L, Paul S, et al. Iroquois proteins promote skeletal joint formation by maintaining chondrocytes in an immature state. *Dev Cell.* 2015;35(3):358–65. [PubMed: 26555055]
51. Gene Expression Image Detail. Mouse Genome Informatics; 2019 [cited 2019 Feb 27]. Available from: [http://www.informatics.jax.org/image/MGI: 4579896](http://www.informatics.jax.org/image/MGI:4579896).
52. Gene Expression Image Detail. Mouse Genome Informatics; 2019 [cited 2019 Feb 27]. Available from: [http://www.informatics.jax.org/assay/MGI: 4822985#euxassay_001489_19_id](http://www.informatics.jax.org/assay/MGI:4822985#euxassay_001489_19_id).
53. Gene Expression Image Detail. Mouse Genome Informatics; 2019 [cited 2019 Feb 27]. Available from: [http://www.informatics.jax.org/assay/MGI: 5422627#DA89_Specimen_DA16_id](http://www.informatics.jax.org/assay/MGI:5422627#DA89_Specimen_DA16_id).
54. Jemtland R, Holden M, Reppe S, et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. *J Bone Miner Res.* 2011;26(8):1793–801. [PubMed: 21452281]
55. Lattanzi W, Barba M, Novegno F, et al. Lim mineralization protein is involved in the premature calvarial ossification in sporadic craniosynostoses. *Bone.* 2013;52(1):474–84. [PubMed: 22982077]
56. Beck TJ, Broy SB. Measurement of hip geometry—technical background. *J Clin Densitom.* 2015;18(3):331–7. [PubMed: 26277850]
57. Yates LB, Karasik D, Beck TJ, Cupples LA, Kiel DP. Hip structural geometry in old and old-old age: similarities and differences between men and women. *Bone.* 2007;41(4):722–32. [PubMed: 17662680]

Table 1.

Discovery, Replication, and Joint Analysis Results

Phenotype	Chr	Position	Top SNP	Discovery (<i>n</i> = 18,719)				Replication (<i>n</i> = 9000+)				Combined (<i>n</i> = 27,053)					
				Frequency	Z-score	<i>p</i>	Het. <i>I</i> ²	Direction	Nearby gene(s)	Frequency	Z-score	<i>p</i>	Het. <i>I</i> ²	Frequency	Z-score	<i>p</i>	Functional annotation
FNL	5	4,380,853	rs261179	0.758	5.288	1.23E-07	0	+++++	IRX1, ADAMTS16	0.7538	1.302	0.01834	0	0.756	5.582	2.37E-08	Intergenic
NNW	5	176,460,183	rs6556301	0.364	5.681	1.35E-08	21.3	-+-----	FGFR4, NSD1, RAB24	0.3644	4.078	0.0176	73.1	0.364	5.583	2.37E-08	Intergenic
NNZ	11	68,618,111	rs7102273	0.724	5.348	8.88E-08	16.7	+++++	LRP5, PPP6R3, GAL*	0.7322	2.937	0.00332	28.2	0.724	6.595	4.25E-11	Intergenic
NNW	12	28,596,065	rs11049605	0.304	5.438	4.80E-08	0	+++++	CCDC91	0.3125	4.361	#####	57.2	0.306	6.908	4.93E-12	Intronic
FNL	21	35,634,458	rs8129030	0.641	4.769	1.85E-06	30.4	----+?=-	RUNX1	0.6306	0.677	0.108	0	0.638	4.732	2.23E-06	Intergenic

Bold values indicate *p* < 5E-08.

Chr = chromosome; FNL = femoral neck length; NNW = narrowest width of the femoral neck; NNZ = femoral neck section modulus.

Table 2. Hip Geometry Associations ($p < 0.000005$) With Genes Previously Associated With BMD

SNP	Region	Chromosome position	Reported gene(s)	Mapped gene	PubMed ID	First author	Journal	HSA Z-score	HSA <i>p</i>	HSA phenotype
rs2450083	8q24.12	119051303	TNFRSF11B	TNFRSF11B COLEC10	24945404	Kemp JP	PLoS Genet	3.648	1.800E-06	NNW
rs7108738	11p15.2	15688538	SOX6	INSC - SOX6	22504420	Estrada K	Nat Genet	-5.000	7.600E-07	NNZ
rs3736228	11q13.2	68433827	LRP5	LRP5	22504420	Estrada K	Nat Genet	-6.000	1.430E-06	NNZ

HSA = Hip Structural Analysis.

Table 3.

Top Hip Geometry SNPs Associations With Adult Stature

Phenotype	Chr	Position	Top SNP	Discovery			HEIGHT (GIANT Consortium)		
				Frequency	Z-score	p	In or near gene(s)	SNP	p
FNL	5	4380853	rs261179	0.76	5.288	1.23E-07	IRX1, ADAMTS16	rs261179	5.85E-01
NNW	5	176460183	rs6556301	0.36	-5.681	1.35E-08	FGFR4, NSD1, RAB24	rs6556301	4.16E-04
NNZ	11	68618111	rs7102273	0.72	5.348	8.88E-08	LRP5, PPP6R3, GAL	rs7102273	1.33E-01
NNW	12	28596065	rs11049605	0.30	5.458	4.80E-08	CCDC91	rs11049605	2.53E-12
FNL	21	35634458	rs8129030	0.6401	-4.769	1.85E-06	RUNX1	rs8129030	8.99E-01

Bold values indicate $p < 5E-08$.

Chr = chromosome; GIANT = Genetic Investigation of Anthropometric Traits; FNL = femoral neck length; NNW = narrowest width of the femoral neck; NNZ = femoral neck section modulus.

Table 4.

Most Significant Hip Geometry SNP Associations With Any Type of Fracture

Phenotype	Chr	Top SNP	HG GWAS			Any type of fracture GWAS					
			Frequency	Z-score	p	In or near gene(s)	A1	A2	Beta	SE	p
FNL	5	rs261179	0.7558	5.288	1.23E-07	IRX1, ADAMTS16	t	c	-0.001	0.01	0.91
NNW	5	rs6556301	0.3642	-5.681	1.35E-08	FGFR4, NSDI, RAB24	t	g	0.016	0.01	0.07
NNZ	11	rs7102273	0.7243	5.348	8.88E-08	LRP5, PPP6R3, GAL*	t	c	-0.037	0.01	7.46E-05
NNW	12	rs11049605	0.3042	5.458	4.80E-08	CCDC91	t	g	0.010	0.01	0.25
FNL	21	rs8129030	0.6379	-4.769	1.85E-06	RUNX1	a	t	0.003	0.01	0.71

Chr = chromosome; FNL = femoral neck length; NNW = narrowest width of the femoral neck; NNZ = femoral neck section modulus.

Table 5.

Correlations of Candidate Gene Transcripts With Hip Geometry Traits

Affymetrix ID	Gene symbol	NSA		FNL		NNW		NNZ	
		r	p	r	p	r	p	r	p
238125_at	ADAMTS16	0.07	0.518	0.13	0.234	-0.13	0.251	0.20	0.082
1570571_at	CCDC91	-0.02	0.893	-0.10	0.388	-0.10	0.358	-0.17	0.121
218545_at	CCDC91	0.12	0.271	-0.03	0.759	0.12	0.277	-0.08	0.491
1554962_a_at	FGFR4	-0.09	0.430	0.04	0.736	-0.04	0.729	0.10	0.384
211237_s_at	FGFR4	0.00	0.994	-0.01	0.942	0.04	0.712	0.21	0.057
208129_x_at	LOC100506403 /// LOC101928269 /// RUNX1	-0.09	0.427	0.06	0.596	0.07	0.518	0.27	0.014
209359_x_at	LOC100506403 /// LOC101928269 /// RUNX1	-0.18	0.101	0.05	0.654	-0.12	0.289	0.23	0.041
209360_s_at	LOC100506403 /// LOC101928269 /// RUNX1	-0.09	0.443	0.00	0.998	-0.08	0.463	0.09	0.415
210365_at	LOC100506403 /// LOC101928269 /// RUNX1	-0.03	0.792	0.11	0.331	0.01	0.920	-0.01	0.956
210805_x_at	LOC100506403 /// LOC101928269 /// RUNX1	0.00	0.986	0.05	0.633	-0.10	0.388	-0.07	0.528
211180_x_at	LOC100506403 /// LOC101928269 /// RUNX1	-0.14	0.230	-0.01	0.934	-0.14	0.216	0.14	0.212
209468_at	LRP5	-0.05	0.634	-0.04	0.722	-0.01	0.930	-0.09	0.428
229591_at	LRP5	-0.07	0.520	0.24	0.036	0.03	0.781	0.03	0.814
219084_at	NSD1	0.13	0.269	-0.08	0.461	0.06	0.605	0.10	0.389
225654_at	NSD1	0.20	0.072	-0.03	0.817	0.15	0.185	0.33	0.003
235760_at	NSD1	0.07	0.519	-0.16	0.149	0.05	0.629	0.04	0.740
243612_at	NSD1	-0.05	0.679	0.05	0.639	-0.13	0.234	-0.08	0.495
217928_s_at	PPP6R3	-0.07	0.530	0.03	0.814	0.02	0.830	0.14	0.231
222467_s_at	PPP6R3	-0.11	0.350	0.01	0.922	-0.13	0.242	0.08	0.466
232312_at	PPP6R3	0.04	0.720	-0.04	0.749	-0.13	0.241	-0.20	0.078
225251_at	RAB24	0.05	0.680	-0.03	0.814	-0.01	0.931	0.03	0.800

Bold values are for correlations with *p* 0.05.

NSA = neck-shaft angle; FNL = femoral neck length; NNW = narrowest width of the femoral neck; NNZ = section modulus of the femoral neck.

Table 6.

eQTLs From Transiliac Biopsies

SNP	Chr	Position	Gene/probe	Beta	t statistics	p
rs2611179	5	4,380,853	–			>0.05
rs2611189	5	4,325,585	–			>0.05
rs6556301	5	176,460,183	PDLIM7	0.121297105	2.952509835	4.99E-03
rs2164198	8	69,577,442	CPA6	0.048952917	2.207793024	3.24E-02
rs12545316	8	68,687,255	–			>0.05
rs7102273	11	68,618,111	PPP6R3	-0.191649382	-3.63881459	7.03E-04
rs10843164	12	28,569,714	CCDC91	-0.124429445	-2.444584818	1.85E-02

Bold values are significant at $p < 0.005$.

eQTL = expression quantitative trait locus; Chr = chromosome.

Table 7.

Expression of Candidate Genes in Murine Bone Cells

Top SNP	Gene(s)	Osteoblast (calvarial)	Osteoclast*	Osteoblast modules	Osteoclast modules
rs261179	IRX1	Increase-plateau	0		
rs261189	ADAMTS16	0	1		
rs6556301	FGFR4	0	0		
	NSD1	0	1		
	RAB24	Slight decrease	1		
rs7102273	LRP5	Increase	1		6, 9
	PPP6R3	0	1		6
	GAL	0	0		
rs11049605	CCDC91	0	1		
rs8129030	RUNX1	0	1		

* 0 = absent; 1 = present.